SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

HC Wainwright & Co. Maintains Buy on Clovis Oncology, Raises Price Target to $33

HC Wainwright & Co. maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and raises the price target from $29 to $33.

Benzinga · 05/18/2020 10:59

HC Wainwright & Co. maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and raises the price target from $29 to $33.